Marie‐paule Kieny
#155,295
Most Influential Person Now
Marie‐paule Kieny's AcademicInfluence.com Rankings
Marie‐paule Kienybiology Degrees
Biology
#11924
World Rank
#15359
Historical Rank
Virology
#286
World Rank
#293
Historical Rank
Immunology
#786
World Rank
#809
Historical Rank

Download Badge
Biology
Marie‐paule Kieny's Degrees
- PhD Immunology University of Strasbourg
Why Is Marie‐paule Kieny Influential?
(Suggest an Edit or Addition)Marie‐paule Kieny's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results (2020) (2026)
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) (2017) (716)
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial (2015) (685)
- Cost–effectiveness thresholds: pros and cons (2016) (467)
- The 2009 A (H1N1) influenza virus pandemic: A review. (2010) (454)
- Expression of rabies virus glycoprotein from a recombinant vaccinia virus (1984) (426)
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. (2016) (389)
- Monitoring Progress towards Universal Health Coverage at Country and Global Levels (2014) (375)
- SARS-CoV-2 variants and ending the COVID-19 pandemic (2021) (374)
- Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. (1991) (350)
- Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. (1984) (349)
- Delivering Quality Health Services: A Global Imperative for Universal Health Coverage (2018) (306)
- Medication Without Harm: WHO's Third Global Patient Safety Challenge (2017) (289)
- Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine (1991) (276)
- Oral vaccination of the fox against rabies using a live recombinant vaccinia virus (1986) (247)
- The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. (2015) (246)
- Mucosal immunity and tolerance: relevance to vaccine development (1999) (241)
- The international Ebola emergency. (2014) (229)
- New versatile cloning and sequencing vectors based on bacteriophage M13. (1983) (228)
- A review of vaccine research and development: human enteric infections. (2006) (219)
- Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. (1993) (217)
- Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone (1997) (204)
- A review of vaccine research and development: meningococcal disease. (2006) (202)
- Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins (2003) (201)
- First generation leishmaniasis vaccines: a review of field efficacy trials. (2008) (192)
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
- Universal health coverage. (2013) (187)
- A review of vaccine research and development: Human acute respiratory infections (2005) (186)
- Health-system resilience: reflections on the Ebola crisis in western Africa (2014) (176)
- Strengthening health systems for universal health coverage and sustainable development (2017) (175)
- A review of vaccine research and development: the human immunodeficiency virus (HIV). (2006) (172)
- Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. (1991) (168)
- Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. (1992) (160)
- A review of human vaccine research and development: malaria. (2007) (157)
- Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. (1991) (144)
- Developing Global Norms for Sharing Data and Results during Public Health Emergencies (2016) (144)
- Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins (1989) (140)
- A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. (1995) (140)
- Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. (1993) (139)
- Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini. (1984) (135)
- Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. (2008) (134)
- Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. (2016) (133)
- Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. (2011) (132)
- Ebola vaccine--an urgent international priority. (2014) (120)
- Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. (2012) (113)
- Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results (2015) (111)
- Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. (1990) (109)
- Mutational analysis of the HIV nef protein. (1990) (108)
- Priority-setting for achieving universal health coverage (2016) (105)
- Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans (2009) (102)
- Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. (2006) (101)
- Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 (1995) (99)
- Tumour prevention and rejection with recombinant vaccinia (1987) (98)
- Beyond Ebola: a new agenda for resilient health systems (2015) (98)
- Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. (1992) (98)
- Advancing the Right to Health-The Vital Role of Law. (2017) (96)
- MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines (2000) (95)
- Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV (2017) (95)
- Improved antigenicity of the HIV env protein by cleavage site removal. (1988) (94)
- Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. (1991) (94)
- AIDS virus env Protein Expressed from a Recombinant Vaccinia Virus (1986) (92)
- Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy (2012) (88)
- A global pandemic influenza vaccine action plan. (2006) (88)
- Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. (2010) (88)
- WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. (2011) (87)
- Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. (1992) (80)
- Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. (1993) (80)
- USE OF RECOMBINANT VACCINIA-RABIES GLYCOPROTEIN VIRUS FOR ORAL VACCINATION OF WILDLIFE AGAINST RABIES: INNOCUITY TO SEVERAL NON-TARGET BAIT CONSUMING SPECIES (1989) (79)
- Isotypic restriction of the antibody response to human immunodeficiency virus. (1988) (79)
- Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults (2008) (79)
- The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. (2002) (77)
- A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein (1991) (76)
- Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa (1996) (74)
- HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques (1995) (74)
- Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. (2005) (73)
- Qualitative and quantitative analysis of human cytotoxic T‐lymphocyte responses to HIV‐1 proteins (1992) (73)
- Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report (2017) (73)
- The Zika Challenge. (2016) (71)
- Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. (1993) (70)
- Research agenda for mass gatherings: a call to action (2012) (69)
- Global production capacity of seasonal influenza vaccine in 2011. (2013) (69)
- Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication (1988) (67)
- Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization☆ (2017) (63)
- 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003. (2004) (63)
- Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. (1996) (63)
- The third global patient safety challenge: tackling medication-related harm. (2017) (62)
- Data sharing in public health emergencies: a call to researchers (2016) (62)
- Molecular cloning and tissue distribution of a 26-kilodalton Schistosoma mansoni glutathione S-transferase. (1990) (58)
- Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. (1990) (55)
- Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. (1994) (54)
- Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies. (1988) (53)
- Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial (2017) (51)
- A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation (2016) (51)
- Secondary Structure of the 3′ Terminus of Hepatitis C Virus Minus-Strand RNA (2002) (51)
- Production of cholera toxin B subunit in Lactobacillus. (1998) (50)
- Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection (2002) (48)
- Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. (2009) (47)
- Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence (1990) (47)
- Complex systems analysis: towards holistic approaches to health systems planning and policy. (2011) (45)
- On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa. (2016) (44)
- A review of vaccine research and development: tuberculosis. (2005) (44)
- Assembling a global vaccine development pipeline for infectious diseases in the developing world. (2006) (43)
- Development of a Vaccinia-Rabies Glycoprotein Recombinant Virus Vaccine (1988) (42)
- Multiple subsets of HIV‐specific cytotoxic T lymphocytes in humans and in mice (1989) (41)
- Cholera in disasters: do vaccines prompt new hopes? (2008) (41)
- Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. (1992) (41)
- World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development (2018) (40)
- Malaria vaccine development: progress and challenges. (2006) (40)
- An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. (1990) (40)
- Development of vaccines against influenza H5. (2006) (40)
- Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure (2018) (39)
- Development and evaluation of influenza pandemic vaccines (2006) (38)
- Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain (1993) (37)
- The impact of globalization on vaccine development and availability. (2006) (36)
- High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. (1996) (35)
- The Evolution of the Meningitis Vaccine Project (2015) (35)
- Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. (1997) (35)
- H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. (2016) (34)
- Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. (2019) (34)
- Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. (2010) (34)
- HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines (2004) (34)
- Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. (2004) (33)
- Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. (2009) (32)
- Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins. (2003) (31)
- Production of a non-functional nef protein in human immunodeficiency virus type 1-infected CEM cells. (1990) (30)
- Human vaccine research and development: an overview. (2005) (30)
- Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. (1989) (30)
- Use of vaccinia rabies recombinant for oral vaccination of wildlife. (1990) (30)
- Ethical considerations related to the provision of care and treatment in vaccine trials. (2007) (30)
- Research and development of new vaccines against infectious diseases. (2004) (29)
- Persistence of Pathogenic Challenge Virus in Macaques Protected by Simian Immunodeficiency Virus SIVmacΔnef (2001) (28)
- Human resources for universal health coverage: from evidence to policy and action. (2013) (26)
- Recombinant cholera toxin B subunit in Escherichia coli: high-level secretion, purification, and characterization. (1994) (26)
- HIV-1 core proteins expressed from recombinant vaccinia viruses. (1989) (26)
- Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. (1991) (25)
- 2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges. (2012) (25)
- Immunization safety priority project at the World Health Organization. (2003) (25)
- Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. (1995) (25)
- WHO R&D Blueprint: a global coordination mechanism for R&D preparedness (2017) (25)
- Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. (1990) (24)
- Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans (2018) (24)
- The need for global R&D coordination for infectious diseases with epidemic potential (2016) (23)
- Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. (2000) (23)
- Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002. (2003) (23)
- Interaction between rabies infection and oral administration of vaccinia-rabies recombinant virus to foxes (Vulpes vulpes). (1989) (23)
- Tough decisions on essential medicines in 2015 (2015) (22)
- Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial (2017) (22)
- M13 bacteriophage vectors for the expression of foreign proteins in Escherichia coli: the rabies glycoprotein. (1984) (22)
- Patent pooling to increase access to essential medicines (2019) (22)
- Trypsin-resistant gp120 receptors are upregulated on short-term cultured human epidermal Langerhans cells. (1991) (22)
- HIV‐specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus (1988) (22)
- Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (2010) (22)
- Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA). (1991) (21)
- DNA binding factors that bind to the negative regulatory element of the human immunodeficiency virus-1: regulation by nef. (1990) (21)
- Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies (2002) (21)
- Effi cacy and eff ectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial (2015) (20)
- The 2014 Ebola outbreak: ethical use of unregistered interventions (2014) (20)
- Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. (1990) (19)
- Seasonal vaccines – Critical path to pandemic influenza response (2017) (19)
- Interaction of Human Epidermal Langerhans Cells with HIV‐1 Viral Envelope Proteins (gp 120 and gp 160s) Involves a Receptor‐mediated Endocytosis Independent of the CD4 T4A Epitope (1991) (19)
- Reducing empiricism in malaria vaccine design. (2010) (18)
- Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. (2008) (18)
- Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model (2018) (18)
- Lack of evidence for an immunosuppressive role for MUC1 (1999) (18)
- Technology transfer hub for pandemic influenza vaccine. (2009) (17)
- Lessons learned from Ebola Vaccine R&D during a public health emergency (2018) (16)
- Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. (1994) (16)
- Influenza pandemic vaccines: how to ensure a low-cost, low-dose option (2006) (15)
- Gender, age, and ethnicity in HIV vaccine-related research and clinical trials: Report from a WHO–UNAIDS consultation, 26–28 August 2004. Lausanne, Switzerland (2005) (15)
- Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. (2018) (14)
- The pandemic influenza vaccine challenge. (2008) (14)
- Correction: Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans (2009) (14)
- Cloned antigens and antiidiotypes. (1995) (12)
- In vitro binding and internalization of HIV envelope glycoproteins by human epidermal Langerhans cells does not require the CD4-gp120-binding site. (1990) (12)
- Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. (2006) (12)
- Development of animal recombinant DNA vaccine and its efficacy in foxes. (1988) (12)
- The WHO we want (2020) (12)
- A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs. (1992) (12)
- Different approaches to influenza vaccination. (2006) (12)
- Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers (2015) (12)
- Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report (2019) (12)
- Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody (2000) (12)
- Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization (1994) (11)
- A roadmap for sustainably governing the global antimicrobial commons (2019) (11)
- Structure and regulation of the human AIDS virus. (1990) (11)
- Best practices for sharing information through data platforms: establishing the principles (2016) (11)
- Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. World Health Organization Working Group. (1994) (11)
- [Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat]. (1989) (11)
- Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. (1995) (11)
- An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. (2000) (10)
- Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. (2003) (10)
- Honouring the value of people in public health: a different kind of p-value (2015) (10)
- HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins. (1992) (10)
- Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea (2020) (9)
- The promise of conjugate vaccines for Africa. (2007) (9)
- Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus. (1989) (9)
- Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. (1997) (9)
- Rabies vaccine: traditional and novel approaches. (1987) (8)
- Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1Lai is more commonly recognized than HIV-1MN. (1994) (8)
- Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection (2002) (8)
- Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (8)
- Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth (2001) (8)
- Reboot biomedical R&D in the global public interest (2022) (8)
- Effi cacy and eff ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease : fi nal results from the Guinea ring vaccination , open-label , cluster-randomised trial ( Ebola Ça Suffi t ! ) (2017) (7)
- Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008. (2008) (7)
- Developing a vaccine against Zika (2016) (7)
- Characterization of polyoma virus early proteins expressed from vaccinia virus recombinants. (1988) (7)
- Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived. (2017) (7)
- Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (7)
- Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice. (1995) (7)
- Global platform to inform investments for health R&D (2016) (7)
- Preparedness for Infectious Threats (2007) (7)
- Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor. (1994) (6)
- WHO supports fair access to influenza A (H1N1) vaccine. (2009) (6)
- What if communities held the solutions for universal health coverage? (2019) (6)
- Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors' reply (2018) (6)
- Regulatory policy for research and development of vaccines for public health emergencies (2016) (6)
- Health policy and systems research: building momentum and community (2014) (6)
- Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. 1984. (1992) (6)
- Systems science for universal health coverage (2017) (6)
- Changes in the primary outcome in Ebola vaccine trial – Authors' reply (2016) (5)
- Building the Human Vaccines Project: strategic management recommendations and summary report of the 15–16 July 2014 business workshop (2015) (5)
- Recombinant polyoma--vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents. (1988) (5)
- Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice 1 (2003) (5)
- European Union conference on poverty-related diseases research. (2009) (5)
- Putting health policy and systems research on the map. (2012) (5)
- The E2 trans-activating protein of bovine papillomavirus type 1 (BPV1) is serine-phosphorylated in vivo. (1989) (5)
- Self-association of truncated forms of HIV-1 gp120. (1997) (5)
- Antiplatelet antibodies during the course of HIV-preventive vaccine trial. (1996) (4)
- The HIV Nef protein: facts and hypotheses. (1992) (4)
- [COVID-19 vaccination for cancer patients: Medical and ethical need]. (2021) (4)
- Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles. (2007) (4)
- Preparedness for infectious threats: public-private partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria meningitidis ACW135 polysaccharide vaccine. (2007) (4)
- New influenza A(H1N1) vaccine: How ready are we for large-scale production? (2009) (4)
- In vivo delivery of interleukin-6 using vaccinia virus: effects on T lymphocytes in nude mice. (1991) (4)
- Isolation of recombinant partial gag gene product p18 (HIV-1Bru) from Escherichia coli. (1989) (4)
- Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. (2009) (4)
- A vaccine against malaria: a substantial step forward (2009) (3)
- Public health: Use open data to curb Zika virus (2016) (3)
- Europe and the century of biomedical discovery and implementation. (2011) (3)
- Health Systems Global, the new international society for health systems research. (2012) (3)
- Towards access 2030 (2017) (3)
- French research strategy to tackle antimicrobial resistance (2020) (3)
- Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination). (2021) (3)
- Effi cacy and eff ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: fi nal results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffi t!) (2017) (2)
- Monitoring progress towards universal health coverage: recent developments. (2014) (2)
- A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project (2022) (2)
- [Experience with antirabies vaccination of foxes using the oral route coordinated among several European countries and perspectives on the use of recombinant vaccinia-rabies virus]. (1988) (1)
- Systematic Analysis of Evidence and Sound Expert Assessment: Two Enablers of Evidence‐Based Decision‐Making in Health (2018) (1)
- Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics. (2022) (1)
- AIDS Vaccine Development: Challenges and Opportunities (2007) (1)
- Candidate vaccines for HIV (1989) (1)
- [HIV envelope proteins are bound by human epidermal Langerhans cells by a binding site which differs from the site on the CD4 molecule, and are internalized by receptor endocytosis]. (1989) (1)
- [Experimental vaccination against HIV-1 protects the chimpanzee against challenge with injections of infected lymphocytes]. (1992) (1)
- One attack on a health worker is one too many (2017) (1)
- Satellite Symposium on Challenges to Enteric Vaccines (2007) (1)
- [Malaria vaccines: state of advancement]. (2003) (1)
- Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020) (1)
- Vaccination against papovavirus-induced tumours using vaccinia recombinants expressing non-structural proteins (1989) (1)
- viral vector and recombinant DNA coding for the F protein of the virus causative agent of AIDS, cell culture infected by this vector, method of preparing the protein, protein obtained, vaccine and antibody obtained (1986) (0)
- Proteine antigenique de la rage glycosylee (1984) (0)
- Antitumor compilation of immunogenic polypetiden with altered zellokalisierung (1998) (0)
- Vectors for expressing a antigenic rabies protein in eucaryotic cells and their application in the preparation of a vaccine (1983) (0)
- New expression vectors of the antigenic protein of rabies and their application in the preparation of vaccines (1982) (0)
- Satellite Symposium on Challenges to Enteric Vaccines: Salvador de Bahia, Brazil, 12 June 2005 (2007) (0)
- A pharmaceutical composition against tumors and infections caused by papilloma viruses (1997) (0)
- Alteration ofV3LoopContext within theEnvelope ofHuman Immunodeficiency Virus Type1Enhances Neutralization (1994) (0)
- Vaccinia/polyoma recombinant virus: A model for tumour immunity (1987) (0)
- Pharmaceutical composition for the treatment or prevention of malignant tumors (1991) (0)
- Eradication of Sylvatic Rabies Using a Live Recombinant Vaccinia-Rabies Vaccine (1993) (0)
- Secondary Structure of the 3 (cid:2) Terminus of Hepatitis C Virus Minus-Strand RNA (2002) (0)
- Protein, dna sequence, poxviruses, and cell culture process, as well as pharmaceutical compositions thereof, useful in the prevention of schistosomiasis (1986) (0)
- Fifth International Conference on AIDS : the Scientific and Social Challenge; plenary session; synthesis (1989) (0)
- viral vector and recombinant DNA coding for a glycoprotein of the virus causative agent of AIDS, cell culture infected by this vector, process for the preparation of the glycoprotein, glycoprotein obtained, vaccine and antibody obtained (1986) (0)
- An antitumor composition was immunogenic polypeptide basic cellular localization modified (1997) (0)
- Vaccinia Recombinants Expressing Foreign Antigens: Antiviral and Antitumor Immunity (1989) (0)
- Viral vector coding for a glycoprotein of the virus responsible for AIDS vaccine, comprising the virus vector or the glycoprotein, as well as antibody to the glycoprotein (1987) (0)
- Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. (1991) (0)
- Detection of gag-Specific Cytotoxic T Lymphocytes in HIV-2ben-Infected Macaques (1992) (0)
- New Engineered Proteins for Use in Therapy and Vaccine Design (1990) (0)
- LOSS OF CD4 MEMBRANE EXPRESSION AND CD4 rnRNA DURING ACUTE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BY PATRICK SALMON,* (2003) (0)
- A pharmaceutical composition against tumors and infections papillomavirus (1996) (0)
- Rabies vaccine and methods for preparing. (1985) (0)
- Vaccine against rabies, as well as process for their preparation (1985) (0)
- From vaccines to global health to vaccines (2018) (0)
- A pharmaceutical composition for the treatment of papillomavirus tumors and infection (1997) (0)
- Expression of human il-2 in mammalian cells by a pox virus recombines (1985) (0)
- Proteins with glutathione S-transferase activity, DNA sequences, antibodies, pox viruses and drugs for prevention of schistosomiasis. (1987) (0)
- A phase 1 clinical trial with a recombinant vaccinia virus expressing MUC1 and IL2 (1997) (0)
- Perspectives on sexual transmission of Ebola virus: complementarity between research and public health intervention (2017) (0)
- A pharmaceutical composition comprising a viral vector (1987) (0)
- infections caused by papilloma viruses pharmaceutical composition against tumors and (1997) (0)
- Expression vectors antigenic protein of rabies in eukaryotic cells and their application in the preparation of a vaccine (1983) (0)
- [AIDS: vaccination against HIV]. (1992) (0)
- Breast cancer immunotherapy: Preclinical study of a recombinant vaccinia virus vector expressing Muc1 and IL2 (1997) (0)
- Towards a breast cancer vaccine (1989) (0)
- Vaccination against rabies and process for its preparation (1984) (0)
- antigenic protein of glycosylated rage (1984) (0)
- Expression of a tumor-specific antigen, a recombinant virus vector as well as its application to the serving or curative treatment of the corresponding tumor. (1987) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Marie‐paule Kieny?
Marie‐paule Kieny is affiliated with the following schools: